Drug Details
| General Information of the Drug (ID: DR7137) | ||||
|---|---|---|---|---|
| Name |
25-methoxyl-dammarane-3beta, 12beta, 20-triol
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Artemisinin | Artemisia annua | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [1] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PRSS50 | Molecule Info | ||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| ER7530 | Breast cancer | Homo sapiens | ||||
| Experimental
Result(s) |
25-methoxyl-dammarane-3beta, 12beta, 20-triol and artemisinin synergistically inhibit MDA-MB-231 cell proliferation through downregulation of testes-specific protease 50 (TSP50) expression. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor A (VEGFA) | Molecule Info | [2] | |
| KEGG Pathway | Ras signaling pathway | Click to Show/Hide | ||
| 2 | Rap1 signaling pathway | |||
| 3 | Cytokine-cytokine receptor interaction | |||
| 4 | HIF-1 signaling pathway | |||
| 5 | mTOR signaling pathway | |||
| 6 | PI3K-Akt signaling pathway | |||
| 7 | VEGF signaling pathway | |||
| 8 | Focal adhesion | |||
| 9 | Pathways in cancer | |||
| 10 | Proteoglycans in cancer | |||
| 11 | MicroRNAs in cancer | |||
| 12 | Renal cell carcinoma | |||
| 13 | Pancreatic cancer | |||
| 14 | Bladder cancer | |||
| 15 | Rheumatoid arthritis | |||
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| 2 | EGFR1 Signaling Pathway | |||
| 3 | TGF_beta_Receptor Signaling Pathway | |||
| 4 | TSH Signaling Pathway | |||
| 5 | Leptin Signaling Pathway | |||
| 6 | FSH Signaling Pathway | |||
| Panther Pathway | Angiogenesis | Click to Show/Hide | ||
| 2 | VEGF signaling pathway | |||
| Pathway Interaction Database | Glypican 1 network | Click to Show/Hide | ||
| 2 | HIF-2-alpha transcription factor network | |||
| 3 | Beta3 integrin cell surface interactions | |||
| 4 | S1P3 pathway | |||
| 5 | Signaling events mediated by TCPTP | |||
| 6 | S1P1 pathway | |||
| 7 | Alpha9 beta1 integrin signaling events | |||
| 8 | Integrins in angiogenesis | |||
| 9 | VEGFR1 specific signals | |||
| 10 | HIF-1-alpha transcription factor network | |||
| Reactome | Platelet degranulation | Click to Show/Hide | ||
| 2 | Regulation of gene expression by Hypoxia-inducible Factor | |||
| 3 | VEGF ligand-receptor interactions | |||
| 4 | VEGF binds to VEGFR leading to receptor dimerization | |||
| WikiPathways | SIDS Susceptibility Pathways | Click to Show/Hide | ||
| 2 | Hypertrophy Model | |||
| 3 | Endochondral Ossification | |||
| 4 | Focal Adhesion | |||
| 5 | Differentiation Pathway | |||
| 6 | Bladder Cancer | |||
| 7 | Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | |||
| 8 | Nifedipine Activity | |||
| 9 | Aryl Hydrocarbon Receptor | |||
| 10 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 11 | Integrated Pancreatic Cancer Pathway | |||
| 12 | Oncostatin M Signaling Pathway | |||
| 13 | Allograft Rejection | |||
| 14 | Integrated Breast Cancer Pathway | |||
| 15 | Signaling by VEGF | |||
| 16 | Heart Development | |||
| 17 | Angiogenesis | |||
